X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.120
-0.050 (-1.58%)
Nov 13, 2026, 4:00 PM EST - Market closed
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $2.88M in the quarter ending September 30, 2026, with 63.12% growth. This brings the company's total for the last twelve months to $16.96M, down -50.08% year-over-year. In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth. That makes X4 Pharmaceuticals the 34,780th largest company in the world by revenue and 4,571st in the United States.
Revenue (ttm)
$16.96M
Revenue Growth
-50.08%
P/S Ratio
18.78
Revenue / Employee
$376,911
Employees
45
Market Cap
318.59M
Revenue by Geography
- United Kingdom 28.60M 81.5%
- United States 6.50M 18.5%
Fiscal year ended Dec 31, 2025 See the full X4 Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 137.43M |
| Agenus | 133.95M |
| Enanta Pharmaceuticals | 65.26M |
| Scribe Therapeutics | 33.30M |
| Ocugen | 4.78M |
| ProKidney | 818.00K |
| Inhibikase Therapeutics | 1.00 |
XFOR News
- 1 day ago - X4 Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 3 days ago - X4 Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - X4 Pharmaceuticals reports Q3 EPS (16c), consensus (19c) - TheFly
- 9 days ago - X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 9 days ago - X4 Pharmaceuticals Earnings release: Q3 2026 - Filings
- 10 days ago - X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 - GlobeNewsWire
- 15 days ago - X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day - GlobeNewsWire